Benign Prostatic Hyperplasia Therapeutics Market to Reach $9.39 Bn, Globally, by 2030 at 5.0% CAGR: Allied Market Research

News provided by

Feb 22, 2022, 08:10 ET

PORTLAND, Ore., Feb. 22, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class (Alpha Blocker, 5-Alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, and Others) and Therapy Type (Mono Drug Therapy and Combination Drug Therapy): Global Opportunity Analysis and Industry Forecast, 2021–2030." According to the report, the global benign prostatic hyperplasia therapeutics industry generated $5.69 billion in 2020, and is expected to reach $9.39 billion by 2030, witnessing a CAGR of 5.0% from 2021 to 2030.

For Right Perspective and Competitive Insights, Get Sample Report at:

https://www.alliedmarketresearch.com/request-sample/4708

Drivers, Restraints, and Opportunities

Increase in prevalence of benign prostatic hyperplasia, rise in awareness toward urological disorders, and surge in healthcare expenditure worldwide drive the growth of the global benign prostatic hyperplasia therapeutics market. However, preference for minimally invasive surgical therapies restrains the market growth. On the other hand, huge number of products in the pipeline and opportunities in untapped geographies create new opportunities in the coming years.

Covid-19 Scenario

A large number of hospitals across the globe restructured their staff to raise the capacity for patients diagnosed with Covid-19. This led to postponement of non-elective procedures including benign prostatic hyperplasia.
The manufacturing activities of benign prostatic hyperplasia therapeutics and transportation of raw materials were disrupted due to lockdown. This impacted the overall revenue of the market.

The alpha blockers segment to maintain its lead position during the forecast period

Based on therapeutic class, the alpha blockers segment contributed to the largest share in 2020, holding nearly three-fifths of the global benign prostatic hyperplasia therapeutics market, and is projected to maintain its lead position during the forecast period. This is due to rise in availability of various branded as well as generic drugs for treatment. However, the 5-alpha reductase inhibitors segment is estimated to manifest the highest CAGR of 6.5% from 2021 to 2030, owing to rapid suppression of dihydrotestosterone (DHT) that affects tissue growth in the prostate.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert: https://www.alliedmarketresearch.com/purchase-enquiry/4708

The mono drug therapy segment to maintain its lead in terms of revenue during the forecast period

Based on therapy, the mono drug therapy segment accounted for the highest share in 2020, contributing to more than three-fourths of the global benign prostatic hyperplasia therapeutics market, and is estimated to maintain its lead in terms of revenue during the forecast period. This is attributed to increase in the number of BPH cases globally and availability of various mono drugs. However, the combination drug therapy segment is expected to witness the largest CAGR of 6.2% from 2021 to 2030. This is due to approval of combination therapy and various under-trial studies.

North America to maintain its dominance by 2030

Based on region, North America held the largest market share in 2020, accounting for more than two-fifths of the global benign prostatic hyperplasia therapeutics market, and is expected to maintain its dominance by 2030. This is due to increase in benign prostatic hyperplasia cases, robust R&D infrastructure for life science research, surge in adoption of advanced technologies, improved therapeutics, and presence of key players. However, Asia-Pacific is estimated to witness the fastest CAGR of 6.8% from 2021 to 2030, owing to continuous government support for R&D activities for pharmaceutical and biotechnology, increase in public-private investments, and rise in the number of initiatives for urological disorder awareness.

Leading Market Players

Abbott Laboratories
AbbVie (Allergan Plc)
Astellas Pharma Inc.
Boehringer Ingelheim Pharma GmbH & Co. KG
Eli Lilly and Company
GlaxoSmithKline plc.
Merck & Co., Inc. (Merck Sharp & Dohme Corp)
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Limited

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Request for 14 days free trial: https://www.alliedmarketresearch.com/avenue/trial/starter

"We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market."

Trending Reports in Healthcare Industry (Book Now with 10% Discount):

Gene Therapy Market - Global Opportunity Analysis and Industry Forecast, 2020–2030

Brain Health Supplements Market - Global Opportunity Analysis and Industry Forecast, 2020-2030

Rapid Tests Market - Global Opportunity Analysis and Industry Forecast, 2020-2030

COPD and Asthma Devices Market - Global Opportunity Analysis and Industry Forecast, 2020–2030

Veterinary Imaging Market - Global Opportunity Analysis and Industry Forecast, 2020–2030

Autoinjectors Market - Global Opportunity Analysis and Industry Forecast, 2020–2030

In Vitro Diagnostics (IVD) Market - Global Opportunity Analysis and Industry Forecast, 2020–2030

Brain Monitoring Market - Global Opportunity Analysis and Industry Forecast, 2020–2030

Surgical Robotics Market - Global Opportunity Analysis and Industry Forecast, 2020–2030

Lateral Flow Assays Market - Global Opportunity Analysis and Industry Forecast, 2020–2030

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
[email protected]
Web: https://www.alliedmarketresearch.com/reports-store/life-sciences
Follow Us on LinkedIn: https://www.linkedin.com/showcase/life-sciences-industry-research/